127 related articles for article (PubMed ID: 38351548)
41. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
[TBL] [Abstract][Full Text] [Related]
42. Association Between Combined Presence of Hepatitis C Virus and Polymorphisms in Different Genes With Toxicities of Methotrexate and 6-Mercaptopurine in Children With Acute Lymphoblastic Leukemia.
Abdelaziz DH; Elhosseiny NM; Khaleel SA; Sabry NA; Attia AS; El-Sayed MH
Pediatr Blood Cancer; 2016 Sep; 63(9):1539-45. PubMed ID: 27163515
[TBL] [Abstract][Full Text] [Related]
43. DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship?
Harju T; Hurme-Niiranen A; Suo-Palosaari M; Nygaard Nielsen S; Hinttala R; Schmiegelow K; Uusimaa J; Harila A; Niinimäki R
Pharmacogenomics J; 2023 Sep; 23(5):105-111. PubMed ID: 37138020
[TBL] [Abstract][Full Text] [Related]
44. NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia.
Yi ES; Choi YB; Choi R; Lee NH; Lee JW; Yoo KH; Sung KW; Lee SY; Koo HH
Cancer Res Treat; 2018 Jul; 50(3):872-882. PubMed ID: 28903549
[TBL] [Abstract][Full Text] [Related]
45. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?
Zhou H; Li L; Yang P; Yang L; Zheng JE; Zhou Y; Han Y
BMC Cancer; 2018 May; 18(1):516. PubMed ID: 29720126
[TBL] [Abstract][Full Text] [Related]
46. Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia.
Rosenfeld E; Getz KD; Miller TP; Seif AE; Fisher BT; Burrows E; Ramos MJ; De León DD; Aplenc R; Morales KH; Guevara JP
Pediatr Blood Cancer; 2022 Jun; 69(6):e29467. PubMed ID: 34811879
[TBL] [Abstract][Full Text] [Related]
47. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity.
Nygaard U; Toft N; Schmiegelow K
Clin Pharmacol Ther; 2004 Apr; 75(4):274-81. PubMed ID: 15060506
[TBL] [Abstract][Full Text] [Related]
48. [Association between polymorphism of NUDT15 gene and hepatotoxicity induced by 6-MP in children with acute lymphoblastic leukemia].
Wang X; Wang W
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Dec; 38(12):1258-1261. PubMed ID: 34839520
[TBL] [Abstract][Full Text] [Related]
49. Safety and Efficacy of Split-Dose Thiopurine vs Low-Dose Thiopurine-Allopurinol Cotherapy in Pediatric Inflammatory Bowel Disease.
Cococcioni L; Pensabene L; Puoti MG; El-Kouly S; Chadokufa S; Buckingham R; Gaynor E; Saliakellis E; Kiparissi F; Borrelli O
Clin Transl Gastroenterol; 2023 Mar; 14(3):e00544. PubMed ID: 36729814
[TBL] [Abstract][Full Text] [Related]
50. Reducing risk in thiopurine therapy.
Marinaki AM; Arenas-Hernandez M
Xenobiotica; 2020 Jan; 50(1):101-109. PubMed ID: 31682552
[TBL] [Abstract][Full Text] [Related]
51. The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children.
Tanaka Y; Manabe A; Nakadate H; Kondoh K; Nakamura K; Koh K; Utano T; Kikuchi A; Komiyama T
Leuk Res; 2012 May; 36(5):560-4. PubMed ID: 22200619
[TBL] [Abstract][Full Text] [Related]
52. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
Adam de Beaumais T; Jacqz-Aigrain E
Eur J Clin Pharmacol; 2012 Sep; 68(9):1233-42. PubMed ID: 22421815
[TBL] [Abstract][Full Text] [Related]
53. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.
Harms DO; Göbel U; Spaar HJ; Graubner UB; Jorch N; Gutjahr P; Janka-Schaub GE;
Blood; 2003 Oct; 102(8):2736-40. PubMed ID: 12843002
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia.
Singh M; Bhaskar D; Bhatia P; Thakur R; Sharma P; Bansal D; Jain R; Trehan A
Cancer Chemother Pharmacol; 2023 Jul; 92(1):51-56. PubMed ID: 37256334
[TBL] [Abstract][Full Text] [Related]
55. [Tolerability of 6-mercaptopurine in children with acute lymphoblastic leukemia].
Ma XL; Wang B; Guo HY; Zhang YH; Zhu GH; Duan YL; Yang J; Zhang DW; Jin L; Zhang R; Zhang L; Xie J; Wu MY
Zhonghua Er Ke Za Zhi; 2010 Apr; 48(4):289-92. PubMed ID: 20654019
[TBL] [Abstract][Full Text] [Related]
56. Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature.
Witte TN; Ginsberg AL
Can J Gastroenterol; 2008 Feb; 22(2):181-5. PubMed ID: 18299738
[TBL] [Abstract][Full Text] [Related]
57. APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia.
Kim H; Seo H; Park Y; Min BJ; Seo ME; Park KD; Shin HY; Kim JH; Kang HJ
Cancer Res Treat; 2018 Jul; 50(3):823-834. PubMed ID: 28882023
[TBL] [Abstract][Full Text] [Related]
58. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease.
Rahhal RM; Bishop WP
Inflamm Bowel Dis; 2008 Dec; 14(12):1678-82. PubMed ID: 18521913
[TBL] [Abstract][Full Text] [Related]
59. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469
[TBL] [Abstract][Full Text] [Related]
60. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
